MCE products for research use only. We do not sell to patients.

PT2399

MCE China：PT2399

Brand：MedChemExpress (MCE)

Cat. No.HY-108697

CAS：1672662-14-4

Purity：99.93%

Storage：-20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Shipping：Room temperature in continental US; may vary elsewhere.

Description：PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo.

In Vitro：PT2399 (compound 10f) inhibits HIF-2α with an IC50 of 6 nM[3]. PT2399 can bind directly to the HIF-2α PAS B domain, and cripple HIF-2α’s ability to bind to Aryl hydrocarbon receptor nuclear translocator (ARNT)[2]. PT2399 (20 μM) causes off-target toxicity because it inhibits the proliferation of HIF-2α −/− 786-O cells and other cancer cell lines with undetectable HIF-2α[2]. PT2399 (0.2–2 μM; 0-21 days) inhibits 786-O cells soft agar growth[2]. PT2399 represses various HIF target genes in 786-O VHL−/− ccRCC cells, does not suppress HIF-1α-specific targets such as BNIP3[2].

In Vivo：PT2399 inhibits tumor cell proliferation 3.5 fold in renal cell carcinoma (RCC) bearing mice[1]. PT2399 reduces tumor cell density and increases fibrosis in RCC bearing mice[1]. PT2399 (100 mg/kg; oral gavage; every 12 hours) is more active than SU 11248, and inhibits tumor growth in several SU 11248-resistant tumors in RCC bearing mice [1]. PT2399 directly inhibits HIF-2α causes tumor regression in preclinical models of primary and metastatic pVHL-defective ccRCC in an on-target fashion[2].

IC50 & Target：IC50: 6 nM (HIF-2α)[3] In Vitro PT2399 (compound 10f) inhibits HIF-2α with an IC50 of 6 nM[3]. PT2399 can bind directly to the HIF-2α PAS B domain, and cripple HIF-2α’s ability to bind to Aryl hydrocarbon receptor nuclear translocator (ARNT)[2]. PT2399 (20 μM) causes off-target toxicity because it inhibits the proliferation of HIF-2α −/− 786-O cells and other cancer cell lines with undetectable HIF-2α[2]. PT2399 (0.2–2 μM; 0-21 days) inhibits 786-O cells soft agar growth[2]. PT2399 represses various HIF target genes in 786-O VHL−/− ccRCC cells, does not suppress HIF-1α-specific targets such as BNIP3[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PT2399 Related Antibodies Cell Viability Assay[1] Cell Line: 786-O cells

Hot selling product：NADP  | Sodium 2-oxopropanoate-13C3  | Dexmedetomidine  | Giredestrant  | NB-598 (Maleate)  | Tenofovir alafenamide  | 4,6-Dioxoheptanoic acid  | EED226  | Glycolithocholic acid  | VPC-14456

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Chen W, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016 Nov 3;539(7627):112-117.  [Content Brief]

[2]. Cho H, et al. On-Target Efficacy of a HIF2α Antagonist in Preclinical Kidney Cancer Models. Nature. Nature. 2016 Nov 3;539(7627):107-111.  [Content Brief]

[3]. Wehn PM, et al. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4  [Content Brief]